March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
mTOR Inhibition has Similar Effects to Treatment with Substance P in the Cornea of Pseudomonas aeruginosa-Infected BALB/c Mice
Author Affiliations & Notes
  • Megan E. Foldenauer
    Anatomy & Cell Biology, Wayne State University - School of Medicine, Detroit, Michigan
  • Sharon A. McClellan
    Anatomy & Cell Biology, Wayne State University - School of Medicine, Detroit, Michigan
  • Ronald P. Barrett
    Anatomy & Cell Biology, Wayne State University - School of Medicine, Detroit, Michigan
  • Linda D. Hazlett
    Anatomy & Cell Biology, Wayne State University - School of Medicine, Detroit, Michigan
  • Footnotes
    Commercial Relationships  Megan E. Foldenauer, None; Sharon A. McClellan, None; Ronald P. Barrett, None; Linda D. Hazlett, None
  • Footnotes
    Support  R01EY02986, R01EY016058, and P30EY04068
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6131. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Megan E. Foldenauer, Sharon A. McClellan, Ronald P. Barrett, Linda D. Hazlett; mTOR Inhibition has Similar Effects to Treatment with Substance P in the Cornea of Pseudomonas aeruginosa-Infected BALB/c Mice. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6131.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Rapamycin inhibits mTOR, a ubiquitous peptide that signals downstream of the PI3K/Akt cell survival pathway and regulates IL-10 levels. Substance P (SP) is a neuropeptide with a complex role in the infected cornea of BALB/c mice, i.e., exacerbation of inflammatory processes with concurrent up-regulation of growth factor expression. Growth factors (e.g., HGF) signal through the PI3K/Akt/mTOR pathway. This work examines the relationship between SP, mTOR, and the growth factors in a Pseudomonas aeruginosa model of corneal infection.

Methods: : BALB/c mice were injected intraperitoneally with rapamycin (sterile saline controls) or SP (selected experiments) from the day before infection until 3-5 days post-infection (p.i.). Corneas were harvested at days 1, 3 and 5 p.i. for real-time RT-PCR, ELISA, bacterial plate counts, and MPO. Real-time RT-PCR determined mRNA levels of mTOR, STAT-3, pro- and anti-inflammatory cytokines (IL-12p40, IL-10), pro- and anti-apoptotic genes (caspase-3, Bcl-2), and growth factors (EGF, HGF, FGF-7). A select group of these molecules was tested using ELISA. HGF was applied topically to the cornea (1μg/5μl before and after infection) to determine if mTOR could be modulated by this growth factor, the only one elevated in common between the two treatments.

Results: : After infection, the cornea of rapamycin- (and SP, as shown before) vs. control-treated BALB/c mice showed worsened disease. In this regard, rapamycin and SP treatment were similar: they increased clinical scores, MPO levels, bacterial load, and IL-12p40 expression. Both treatments similarly decreased levels of mTOR, STAT-3 (an effector of IL-10 expression), and IL-10. Both treatments also delayed apoptosis (decreased mRNA levels of caspase-3 and increased Bcl-2) in the infected cornea. As with SP-treatment, rapamycin increased mRNA and protein levels of HGF, but was not similar to SP with regard to elevating EGF or FGF-7. Unexpectedly, topical HGF treatment increased mRNA levels of mTOR and IL-10, but also raised levels of pro-inflammatory cytokines (IL-12p40 and IL-1β).

Conclusions: : These data provide evidence that rapamycin and SP treatment similarly downregulate mTOR, STAT-3, and IL-10, while upregulating IL-12p40, and HGF levels after infection. Nonetheless, topical HGF, although able to upregulate mTOR and IL-10 fails to be protective, in that proinflammatory cytokines are upregulated as well.

Keywords: cornea: basic science • growth factors/growth factor receptors • neuropeptides 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×